A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes

Inclusion Criteria

• •Subjects must be a suitable candidate for FDA Approved LASIK.
• •Subjects must have a stable refraction as documented by previous clinical records.
• •Subjects who wear soft contact lenses must discontinue wear at least 3 days prior to preoperative exam or surgery.
• •Subjects who wear gas permeable contact lenses must discontinue wear at least 3 weeks prior to preoperative exam or surgery.
• •Subjects must be at least 18 years of age.
• •Subjects must be willing and able to return for scheduled follow up examinations each day after surgery at the specified time.
• •Subjects must sign and be given a copy of the written Informed Consent form.
• •Subjects with clinically significant dry eye syndrome or clinically significant blepharitis in either eye.
• •Subjects with clinically significant anterior segment pathology, including clinically significant cataracts, corneal scarring or neovascularization in either eye.
• •Subjects who have undergone previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye.
• •Subjects who have a history of Herpes zoster or Herpes simplex keratitis.
• •Subjects on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing, any immunocompromised subjects, and subjects with clinically significant atopic disease, connective tissue disease, or uncontrolled diabetes.
• •Subjects with a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP\>25 mm Hg in either eye.
• •Subjects with macular pathology in either eye.
• •Subjects who are pregnant, lactating, or planning to be pregnant during the course of the study.
• •Subjects with known sensitivity to planned study concomitant medications.
• •Subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.
• •Use of ocular drugs, other than study medications, during the study and within 30 days prior to study entry or any other ocular medication.